All News

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

This year, the FMX Main Stage presenters will be led by Vivek H Murthy, the 21st US Surgeon General. Learn more about him and the 2 other inspiring guests.

The FDA has granted fast track designation to BMS-986446, an anti–microtubule binding region tau antibody in phase 2 trials for early Alzheimer disease.

Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.

Vertanical's VER-01 shows promise in reducing chronic low back pain, outperforming opioids and maintaining relief for over a year.

Public health expert Kelly Moore, MD, MPH, president and CEO of immunize.org, says the news is good for now, but the uninsured could be at future risk.

Measles vaccine coverage must reach 93% to maintain herd immunity but in 1 postelimination outbreak, the level reached only 80% in school-aged children.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

The annual meeting of the American Academy of Family Physicians is a unique chance to choose continuing education on just about any topic a family physician could imagine.

Review FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for UTIs, acute pain, migraine, diabetes, and more.

Public health officials across states and regions are "thinking on their feet" about how best to protect public health given the upheavel in federal vaccine policy, Moore said.

The European Commission granted marketing authorization for the Lilly mAb based on data from the phase 3 TRAILBLAZER-ALZ 2 and 6 clinical trials.

Novo Nordisk aims to revolutionize diabetes care with its resubmission for insulin icodec, a potential first once-weekly basal insulin for type 2 diabetes therapy in adults.

Vaccines for respiratory syncytial virus were found both safe and effective across 100,000 participants and, critically, for older adults and infants.

Your daily dose of the clinical news you may have missed.

Adult vaccine-preventable diseases cost $26.5B annually in the US. See key gaps, barriers, and strategies primary care physicians can use to boost immunization.

"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.